NASDAQ:MDCO - The Medicines Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$24.05 +0.16 (+0.67 %)
(As of 02/21/2019 12:31 PM ET)
Previous Close$23.89
Today's Range$23.63 - $24.06
52-Week Range$16.69 - $41.57
Volume12,136 shs
Average Volume1.09 million shs
Market Capitalization$1.78 billion
P/E Ratio-2.86
Dividend YieldN/A
Beta1.18
The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States. It primarily focuses on developing Inclisiran, a lipid-lowering drug to reduce LDL-cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease or cardiovascular risk-equivalents. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc.; SciClone Pharmaceuticals; and Symbio Pharmaceuticals Limited. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

Receive MDCO News and Ratings via Email

Sign-up to receive the latest news and ratings for MDCO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:MDCO
CUSIP58468810
Phone973-290-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$44.79 million
Book Value$0.34 per share

Profitability

Net Income$-708,370,000.00
Net Margins-668.93%

Miscellaneous

Employees170
Market Cap$1.78 billion
OptionableOptionable

The Medicines (NASDAQ:MDCO) Frequently Asked Questions

What is The Medicines' stock symbol?

The Medicines trades on the NASDAQ under the ticker symbol "MDCO."

How were The Medicines' earnings last quarter?

The Medicines Company (NASDAQ:MDCO) released its quarterly earnings results on Wednesday, October, 25th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.37) by $0.95. The firm had revenue of $16.87 million for the quarter, compared to analysts' expectations of $26.06 million. The Medicines had a negative net margin of 668.93% and a negative return on equity of 1,477.75%. The firm's revenue for the quarter was down 55.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.64) EPS. View The Medicines' Earnings History.

When is The Medicines' next earnings date?

The Medicines is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for The Medicines.

What price target have analysts set for MDCO?

7 analysts have issued twelve-month price objectives for The Medicines' shares. Their forecasts range from $25.00 to $55.00. On average, they anticipate The Medicines' share price to reach $45.50 in the next twelve months. This suggests a possible upside of 89.2% from the stock's current price. View Analyst Price Targets for The Medicines.

What is the consensus analysts' recommendation for The Medicines?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for The Medicines in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for The Medicines.

Has The Medicines been receiving favorable news coverage?

Press coverage about MDCO stock has been trending somewhat negative on Thursday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. The Medicines earned a news impact score of -1.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.

Who are some of The Medicines' key competitors?

Who are The Medicines' key executives?

The Medicines' management team includes the folowing people:
  • Mr. Stephen M. Rodin J.D., Exec. VP, Gen. Counsel & Sec. (Age 43)
  • Mr. Christopher T. Cox, Chief Corp. Devel. Officer and Exec. VP (Age 54)
  • Dr. Clive A. Meanwell, Chief Innovation Officer & Director (Age 61)
  • Mr. Mark Timney, CEO & Director
  • Mr. Christopher Visioli, CFO & Treasurer (Age 43)

Who are The Medicines' major shareholders?

The Medicines' stock is owned by many different of institutional and retail investors. Top institutional investors include Westfield Capital Management Co. LP (6.23%), Iridian Asset Management LLC CT (4.46%), Northern Trust Corp (1.16%), Geode Capital Management LLC (1.07%), Elk Creek Partners LLC (1.03%) and Pinnacle Associates Ltd. (0.97%). Company insiders that own The Medicines stock include Alexander J Denner, Armin M Kessler, Christopher T Cox, Clive Meanwell, Fredric N Eshelman, Mark Timney, Melvin K Spigelman and William Crouse. View Institutional Ownership Trends for The Medicines.

Which major investors are selling The Medicines stock?

MDCO stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Pinnacle Associates Ltd., Northern Trust Corp, MetLife Investment Advisors LLC, Nisa Investment Advisors LLC, Principal Financial Group Inc., Advisors Asset Management Inc. and Louisiana State Employees Retirement System. Company insiders that have sold The Medicines company stock in the last year include Armin M Kessler, Clive Meanwell, Melvin K Spigelman and William Crouse. View Insider Buying and Selling for The Medicines.

Which major investors are buying The Medicines stock?

MDCO stock was bought by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, Westfield Capital Management Co. LP, Oregon Public Employees Retirement Fund, Tekla Capital Management LLC, Elk Creek Partners LLC, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Millennium Management LLC and New York State Common Retirement Fund. Company insiders that have bought The Medicines stock in the last two years include Alexander J Denner, Christopher T Cox, Fredric N Eshelman and Mark Timney. View Insider Buying and Selling for The Medicines.

How do I buy shares of The Medicines?

Shares of MDCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is The Medicines' stock price today?

One share of MDCO stock can currently be purchased for approximately $24.05.

How big of a company is The Medicines?

The Medicines has a market capitalization of $1.78 billion and generates $44.79 million in revenue each year. The company earns $-708,370,000.00 in net income (profit) each year or ($8.40) on an earnings per share basis. The Medicines employs 170 workers across the globe.

What is The Medicines' official website?

The official website for The Medicines is http://www.themedicinescompany.com.

How can I contact The Medicines?

The Medicines' mailing address is 8 SYLVAN WAY, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-290-6000 or via email at [email protected]


MarketBeat Community Rating for The Medicines (NASDAQ MDCO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  435 (Vote Outperform)
Underperform Votes:  321 (Vote Underperform)
Total Votes:  756
MarketBeat's community ratings are surveys of what our community members think about The Medicines and other stocks. Vote "Outperform" if you believe MDCO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDCO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel